Back to search results

Blue Light Exposure for Infection Treatment

This study is looking at how exposure to bright blue light might help your body fight off serious infections like pneumonia, necrotizing soft tissue infection (a severe skin infection), intraabdominal infections (infections inside your belly), or infected joints. Researchers believe that light can influence your body's natural 24-hour cycle (circadian rhythm), which in turn affects your immune system. They want to see if using a special blue light device can reduce inflammation or organ problems in patients aged 18 to 65 who are hospitalized with one of these infections. The main goals are to measure changes in bacteria levels in the lungs for pneumonia patients, and changes in immune system proteins and inflammation markers in the blood for all participants, all within 72 hours.

Study design
This is an interventional study planning to enroll 144 participants. It compares the effects of blue light exposure to regular room lighting.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for this study are taken at 72 hours after you start the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03482245

The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

Recruiting
NAAges 18–65InterventionalBasic science
Washington University School of Medicine
~144 participants
Updated 2026-02-11 on ClinicalTrials.gov
What's tested:Blue Light

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pneumonia: change in bronchoalveolar lavage (BAL) bacteria concentration
Measured over comparing time of randomization and at 72 hours after randomization
+2 more outcomes measured

Conditions

Pneumonia
Necrotizing Soft Tissue Infection
Intraabdominal Infections
Infection Joint

Explore related trials

Abdominal InfectionInfected jointNecrotizing soft tissue infectionPneumoniaSepticemia

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Matthew R Rosengart, MD MPH · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Matthew R Rosengart, MD MPH
[email protected]
314-362-5298
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

greater than or equal to 18 years of age and less than or equal to 65 years of age
one of the following diagnoses requiring inpatient hospital care

Exclusion

traumatic brain injury
blindness
immunocompromised or immunosuppressed state
infection requiring treatment in preceding 30 days
blindness
SARS-CoV-2

What this trial measures

  • Pneumonia: change in bronchoalveolar lavage (BAL) bacteria concentrationcomparing time of randomization and at 72 hours after randomization

    quantification of the change in bacterial colony forming units (CFU) in BAL fluid

  • All groups: change in expression of circadian proteins in circulating immune cellscomparing time of randomization and at 72 hours after randomization

    quantification of the change in blood white blood cell counts

  • All Cohorts: change in serum concentrations of circulating inflammatory mediators in the bloodcomparing time of randomization and at 72 hours after randomization

    quantification of change in serum cytokine concentrations